Navigation Links
Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
Date:6/7/2011

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS).

This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be administered for 21 days followed by a one week rest period in four week cycles.  The primary objective is to determine the hematologic improvement-erythroid (HI-E) response rate as measured by transfusion reduction or independence, in accordance with the International Working Group MDS 2006 criteria. Secondary objectives include determination of the hematologic improvement-neutrophil (HI-N) and hematologic improvement-platelet (HI-P) response rates, and safety.  

This trial follows the recently completed Phase 2 study in non-del 5q MDS reported at the 52nd Annual Meeting of the American Society of Hematology 2010 in Orlando, FL, "Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog, Glutathione-S-transferase P1-1 (GSTP1-1) Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", Raza, A., Galili, N., Smith, S., et al. (Abstract #2910) where evidence of clinical activity was observed in this patient population.  Patients with del 5q MDS have limited treatment options after becoming resistant to Revlimid and represent an important unmet medical need.

Background on MDS and Telintra

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more ce
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Telik Announces Financial Results For 2008 Second Quarter
2. ReceptorBio Announces Diabetes License Agreement With Telik
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. Telik Announces Receipt of Nasdaq Notice
5. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
6. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces New TRAP Drug Discovery Agreement
9. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
10. Telik Reports Preclinical Results at AACR Annual Meeting
11. Telik Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne Holm Rasmussen ... , 1 Department of Medical Biochemistry and Danish ... Aarhus, Aarhus, Denmark , 2 Department of Urology, ... Bladder cancer comprises a broad spectrum of tumors that includes transitional , ...
... Aiguo Zhang, Allora Aguilera, Chate Luu, Ivan Huang,Diana Davis, Chloe Etienne, Yong Song, Reni Thomas,Kris Simonyi, Jim Wong, Quan Nguyen ... Science Group, 2000 Alfred Nobel Drive, , Hercules, CA 94547 , ... The American Society for Cell Biology , December 9-13, 2000 , ... , , , ...
... Data submitted by Dr. Ivan Kaiser, University of Wyoming,Laramie, WY USA , ... , Dr. Ivan Kaisers research involves ... snake venom, such as post-synaptic neurotoxins and hemorrhagic , ... purification, in which students study the principles of protein ...
Cached Biology Technology:Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... be effective in treating kidney disease, report scientists at the ... the online edition of the Proceedings of the National Academies ... drug is rapamycin, also called sirolimus, and is currently used ... new, transplanted kidney. , Over 600,000 people in the ...
... lure of chocolate or the bitter taste of strychnine would ... as to be hard-wired into the brain. Indeed, in studies ... colleagues reported in the January 19, 2006, issue of Neuron ... they said, favor a model for taste encoding in the ...
... is developing a novel gene therapy aimed at selectively ... development of Parkinson's disease. , The gene therapy, described ... Neurology, was designed by Martha Bohn and her laboratory ... , Bohn is Medical Research Council Professor and director ...
Cached Biology News:Scientists discover that widely available drug also helps fight kidney disease 2Scientists discover that widely available drug also helps fight kidney disease 3How taste response is hard-wired into the brain 2Gene therapy 'turns off' mutation linked to Parkinson's disease 2
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... DTT White solid. ... Purity: ≥99% by titration. ... Absorbance: (100 mM, 280 nm):≤0.05. ... or H 2 O. RTECS ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
Biology Products: